Coronary flow reserve after l-thyroxine therapy in Hashimoto’s thyroiditis patients with subclinical and overt hypothyroidism

Oflaz, Hüseyin; Kurt, Ramazan; Şen, Fatma; Onur, Imran; Çımen, Arif Oğuzhan; Elıtok, Ali; Türkmen, Kültiğin; Pamukçu, Burak; Kaşıkçıoğlu, Erdem; Buğra, Zehra; Mercanoğlu, Fehmi; Özbey, Neşe

doi:10.1007/s12020-008-9037-2

Cited by 20 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should be noticed that treatment with levothyroxine (used to correct clinical hypothyroidism) signifi cantly aff ects a patient's infl ammatory profi le, reducing the pro-infl ammatory cytokines, increasing IL-10 levels, and lowering serum IgG concentrations ( 29,30 ). Levothyroxine therapy might therefore improve coronary microvascular function and thereby prevent cardiovascular events (31)(32)(33).…”

Section: Discussionmentioning

confidence: 99%

Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers

Floreani

Mangini

Reig

et al. 2017

American Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers

Floreani

Mangini

Reig

et al. 2017

American Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Oflaz et al (37) with a smaller group of subjects (18 SCH, 24 controls) and adenosine as a stimulus of hyperaemia-endothelium independent vasodilation obtained similar results for CFR (SCH 1.97 ± 0.09 vs. controls 2.58 ± 0.08.The same authors evaluated CFR for LAD before and after the introduction of levothyroxine replacement therapy and showed that there was a significant increase in CFR for LAD in SCH group after six month levothyroxine substitution (2.03 ± 0.13 vs 2.54 ± 0.18) but the study was conducted on only ten patients with SCH (38). Biondi et al (39) also showed a significant difference in CFR between the SCH and control group (SCH 20, control 15), but they induced endotheliumdependent vasodilation and hyperaemia using a cold pressor test as an inducer ( SCH 1.4 ± 0.2 vs. controls 1.9 ± 0.3 p< 0.0001) (39).…”

Section: Discussionmentioning

confidence: 76%

Specific impact of cardiovascular risk factors on coronary microcirculation in patients with subclinical hypothyroidism

Stojković¹,

Nedeljković-Beleslin²,

Tešić³

et al. 2022

J Med Biochemistry

View full text Add to dashboard Cite

Background: Although thyroid hormones have significant effect on cardiovascular system, the impact of subtle thyroid dysfunction such as subclinical hypothyroidism (SCH) remains to be determined. We investigated coronary flow reserve (CFR) in patients with subclinical hypothyroidism. Methods: Thirty-two subjects with SCH and eighteen control subjects with normal serum thyroid hormones and thyroid-stimulating hormone (TSH) levels were included in the study. TSH, free thyroxine, free triiodothyronine, glucose, insulin, HbA1c, cholesterol, triglyceride and plasma levels of C-reactive protein were measured. Coronary diastolic peak flow velocities in left anterior descending coronary artery were measured at baseline and after adenosine infusion. CFR was calculated as the ratio of hyperemic to baseline diastolic peak velocity. Results: CFR values were not significantly different between the two groups (SCH 2.76 ± 0.35 vs controls 2.76 ± 0.42). There was a significant correlation of CFR with waist to hip ratio, hypertension, smoking habits, markers of glucose status (glucose level, HbA1c, insulin level, HOMA IR), cholesterol, LDL-cholesterol and triglyceride levels in SCH group, whereas only cholesterol level showed significant correlation with CFR in controls. There was no correlation between CFR and thyroid hormones. Conclusion: We concluded that there is a different impact of cardiovascular risk factors on CFR in SCH patients compared to healthy control and that these two groups behave differently in the same circumstances under the same risk factors. The basis for this difference could be that the altered thyroid axis “set point” changes the sensitivity of the microvasculature in patients with SCH to known risk factors.

show abstract

“…Some studies have shown that l -thyroxine treatment could improve coronary flow or reduce hyperlipidemia in patients with HT. 32 , 33 By contrast, another study reported that l -thyroxine treatment increased coagulation factor levels and inhibited fibrinolysis, increasing the risk of ischemic stroke. 34 In the present study, an insufficient period of l -thyroxine treatment affected the outcome, whereas l -thyroxine treatment reduced the risk of depression in Taiwan.…”

Section: Discussionmentioning

confidence: 97%

Risk of Depression, Chronic Morbidities, and l-Thyroxine Treatment in Hashimoto Thyroiditis in Taiwan

et al. 2016

View full text Add to dashboard Cite

The aim of this study was to evaluate the risk of depression in and effect of l-thyroxine therapy on patients with Hashimoto thyroiditis (HT) in Taiwan.In this retrospective, nationwide cohort study, we retrieved data from the Longitudinal Health Insurance Database 2000. We collected data of 1220 patients with HT and 4880 patients without HT for the period 2000 to 2011. The mean follow-up period for the HT cohort was 5.77 years. Univariate and multivariate Cox proportional hazards regression models were used to estimate the risk of depression in the HT cohort.In the HT cohort, 89.6% of the patients were women. Compared with the non-HT cohort, the HT cohort exhibited a higher prevalence of diabetes mellitus, hyperlipidemia, and coronary artery disease. Furthermore, the HT cohort showed a higher overall incidence of depression compared with the non-HT cohort (8.67 and 5.49 per 1000 person-year; crude hazard ratio [HR] = 1.58, 95% confidence interval [CI] = 1.18–2.13). The risk of depression decreased after administration of l-thyroxine treatment for more than 1 year (adjusted HR = 1.02; 95% CI = 0.66–1.59).In Taiwan, the overall incidence of depression was greater in the young HT cohort. l-thyroxine treatment reduced the risk of depression.

show abstract

Coronary flow reserve after l-thyroxine therapy in Hashimoto’s thyroiditis patients with subclinical and overt hypothyroidism

Abstract: Subclinical as well as overt hypothyroid patients have impaired coronary microvascular function which improved after L: -thyroxine therapy. Treatment of Hashimoto's thyroiditis patients with subclinical hypothyroidism should be considered to improve cardiovascular disease risk.

Cited by 20 publications

References 39 publications

Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers

Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers

Specific impact of cardiovascular risk factors on coronary microcirculation in patients with subclinical hypothyroidism

Risk of Depression, Chronic Morbidities, and l-Thyroxine Treatment in Hashimoto Thyroiditis in Taiwan

Contact Info

Product

Resources

About